---
title: "Cognition Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295147829.md"
datetime: "2026-08-06T21:30:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295147829.md)
  - [en](https://longbridge.com/en/news/295147829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295147829.md)
generator: "portal-rs"
---

# Cognition Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.04.

EBIT: As of FY2026 Q2, the actual value is USD -3.929 M.

The provided reference, a Form 8-K filing by Cognition Therapeutics, Inc., states that actual financial and operational metrics, cash flow data, unique metrics, or any forward-looking outlook/guidance are not contained within this specific document. These details are indicated to be furnished as Exhibit 99.1, which is not part of the text provided for analysis. Therefore, no financial or operational metrics can be extracted from the given reference.

### Related Stocks

- [CGTX.US](https://longbridge.com/en/quote/CGTX.US.md)

## Related News & Research

- [Cognition Therapeutics Q2 net loss narrows on lower R&D costs](https://longbridge.com/en/news/295139858.md)
- [Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website](https://longbridge.com/en/news/292481427.md)
- [Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosis](https://longbridge.com/en/news/290686799.md)
- [Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027](https://longbridge.com/en/news/288717735.md)
- [Cambridge Cognition Publishes 2025 Annual Report and Sets May AGM](https://longbridge.com/en/news/284020943.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**